Company intelligence / Profile preview
Dongbao Zixing (Hangzhou) Biomedical Co., Ltd.
Hangzhou, Zhejiang Sheng, Chinathdb.com ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
Dongbao Zixing is advancing novel small molecule and peptide therapeutics targeting metabolic and endocrine disorders. Its lead assets include dual and triple receptor agonists/inhibitors for obesity, gout, and type 2 diabetes. The most advanced programs have reached Phase 2 clinical trials as of early 2025. Clinical results have not been publicly detailed yet.
- Therapeutic areas
- Metabolic DisordersEndocrinologyRheumatology
- Modalities
- Small molecule drugsSynthetic peptides
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
WuXi AppTec
Beyond the preview
Go deeper on Dongbao Zixing (Hangzhou) Biomedical Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dongbao Zixing (Hangzhou) Biomedical Co., Ltd..